Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants a cohort study

JAMA Pediatrics

Volumn 167, Issue 12, 2013, Pages 1118-1124

  Winterstein, Almut G ^a,c   Knox, Caitlin A ^a   Kubilis, Paul ^a   Hampp, Christian ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Center for Drug Evaluation and Research   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

AGE; ARTICLE; BIRTH CERTIFICATE; CHILD HOSPITALIZATION; COHORT ANALYSIS; FEMALE; FOLLOW UP; GESTATIONAL AGE; HIGH RISK POPULATION; HOSPITAL BILLING; HOSPITAL PATIENT; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; INFANT; INFECTION RISK; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; NONHUMAN; OUTCOME ASSESSMENT; OUTPATIENT CARE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; SEASONAL VARIATION; SIBLING; SURVIVAL TIME; UNITED STATES;

AGE FACTORS; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FLORIDA; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RETROSPECTIVE STUDIES; RISK FACTORS; TEXAS;

EID: 84890070672     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2013.2636     Document Type: Article

References (48)

1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-1446.
2. Hall CB,Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6): 588-598.
3. Winterstein AG, Hampp C, Saidi A. Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf. 2012;21(1):53-60.
4. Berger TM, Aebi C, Duppenthaler A, Stocker M; Swiss Pediatric Surveillance Unit. Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005). Infection. 2009;37(2):109-116.
5. Prais D, Schonfeld T, Amir J; Israeli Respiratory Syncytial Virus Monitoring Group. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis. Pediatrics. 2003;112(3, pt 1):548-552.
6. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child. 2004;89(10):961-965.
7. Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000. BMC Pediatr. 2004;4(1):25.
8. Boyce TG, Mellen BG, Mitchel EF Jr,Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137(6):865-870.
9. Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, LanariM. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis. 2008;27(10):891-899.
10. Martin JA, Kung HC, Mathews TJ, et al. Annual summary of vital statistics: 2006. Pediatrics. 2008;121(4):788-801.
11. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6, pt 1):1442-1446.
12. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements: modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701.
13. Meissner HC, Bocchini JA Jr, Brady MT, Hall CB, Kimberlin DW, Pickering LK. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Pediatrics. 2009;124(6):1676-1679.
14. Centers for Disease Control and Prevention. Respiratory syncytial virus: United States, July 2007-June 2011. MMWR Morb Mortal Wkly Rep. 2011;60(35):1203-1206.
15. Krilov LR,Weiner LB, Yogev R, et al. The 2009 COID recommendations for RSV prophylaxis. Pediatrics. 2009;124(6):1682-1684.
16. Rossi GA, Silvestri M, LanariM. Should the American Academy of Pediatrics respiratory syncytial virus guidelines be modified? Pediatrics. 2010;125(4):e1021; author reply e1022.
17. Kaiser Family Foundation. State health facts. http://kff.org/statedata/. Accessed August 12, 2011.
18. Centers for Disease Control and Prevention. The National Respiratory and Enteric Virus Surveillance System (NREVSS). http://www.cdc.gov /surveillance/nrevss/rsv/default.html. Accessed January 10, 2013.
19. Hampp C, Saidi AS,Winterstein AG. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr. 2010;156(6):953-959; e1.
20. Martin J, Kirmeyer S, Osterman M, Shepherd RA. Born a Bit Too Early: Recent Trends in Late Preterm Births. Vol 24. Hyattsville, MD: National Center for Health Statistics; 2009.
21. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer; 2001.
22. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, FL: CRC Press; 1994.
23. Gerlach R, Stamey J. Bayesian model selection for logistic regression with misclassified outcomes. Stat Modelling. 2007;7(3):255-273. doi:10.1177/1471082X0700700303.
24. Mansbach JM, McAdam AJ, Clark S, et al. Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department. Acad Emerg Med. 2008;15(2):111-118.
25. Flaherman V, Li S, Ragins A, Masaquel A, Kipnis P, Escobar GJ. Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system. Clin Ther. 2010;32(13):2220-2229.
26. Hampp C. Utility of Current Surveillance Systems to Detect Respiratory Syncytial Virus Seasons and Implications for Immunoprophylaxis [dissertation]. Gainesville: University of Florida; 2009. http://etd.fcla.edu/UF/UFE0024726/ hamppc.pdf. Accessed January 10, 2013.
27. Hampp C, Asal N, Lipowski E, et al. Validity of laboratory-based surveillance for detection of respiratory syncytial virus seasons. Am J Epidemiol. 2013;177(8):841-851.
28. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23(9):815-820.
29. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27(9):788-793.
30. Park HW, Lee BS, Kim AR, et al. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age. Pediatr Infect Dis J. 2012;31(8):e99-e104.
31. Pezzotti P, Mantovani J, Benincori N, Mucchino E, Di Lallo D. Incidence and risk factors of hospitalization for bronchiolitis in preterm children. BMC Pediatr. 2009;9:56.
32. Doering G, GusenleitnerW, Belohradsky BH, Burdach S, Resch B, Liese JG. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age. Pediatr Infect Dis J. 2006;25(12):1188-1190.
33. Eriksson M, Bennet R, Rotzén-Ostlund M, von SydowM,Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002;91(5):593-598.
34. Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999;104(4, pt 1):894-899.
35. Carbonell-Estrany X, Quero J, Bustos G, et al; IRIS Study Group. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation. Pediatr Infect Dis J. 2000;19(7):592-597.]
36. Figueras Aloy J, Carbonell Estrany X; Comité de Estándares de la Sociedad Española de Neonatología. Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation) [in Spanish]. An Pediatr (Barc). 2010;73(2):e1-e4.
37. Fryzek JP, MartoneWJ, Groothuis JR. Trends in chronologic age and infant respiratory syncytial virus hospitalization. Adv Ther. 2011;28(3):195-201.
38. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23(9):806-814.
39. Paes B, Steele S, JanesM, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin. 2009;25(7):1585-1591.
40. Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB; European RSV Risk Factor Study Group. Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation. J Perinat Med. 2010;38(4):411-417.
41. Simões EA, Carbonell-Estrany X, Fullarton JR, et al; European RSV Risk Factor Study Group. a predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res. 2008;9:78.
42. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, LanariM; European RSV Risk Factor Study Group. European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus. J Matern Fetal Neonatal Med. 2011;24(1):152-157.
43. Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J. 2010;29(4):374-376.
44. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus. J Perinatol. 2008;28(7):511-517.
45. Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiologic studies. J Clin Epidemiol. 1989;42(10):937-945.
46. Crystal S, Akincigil A, Bilder S,Walkup JT. Studying prescription drug use and outcomes with Medicaid claims data. Med Care. 2007;45(10) (suppl 2):S58-S65.
47. Hennessy S, Bilker WB,Weber A, Strom BL. Descriptive analyses of the integrity of a USMedicaid claims database. Pharmacoepidemiol Drug Saf. 2003;12(2):103-111.
48. Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care. 2007;45(12):1216-1220.